In a report released today, Soumit Roy from JonesTrading maintained a Hold rating on Inhibikase Therapeutics (IKT – Research Report). The company’s shares closed today at $2.17.
According to TipRanks, Roy is an analyst with an average return of -5.0% and a 27.03% success rate. Roy covers the Healthcare sector, focusing on stocks such as Oncolytics Biotech, Anavex Life Sciences, and Cassava Sciences.
Currently, the analyst consensus on Inhibikase Therapeutics is a Moderate Buy with an average price target of $27.00.
See today’s best-performing stocks on TipRanks >>
Based on Inhibikase Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $116.41 thousand and a GAAP net loss of $5.78 million. In comparison, last year the company earned a revenue of $6.55 thousand and had a GAAP net loss of $4.64 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inhibikase Therapeutics Inc is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Diseases and related disorders inside and outside the brain. Its pipeline product, IkT-148009, targets underlying disease mechanisms to reverse the course of Parkinson’s disease and the GI complications of Parkinson’s disease.
Read More on IKT:
- Inhibikase Therapeutics completes 501 bioequivalence study of IkT-001Pro
- Inhibikase Therapeutics reports Q2 EPS ($1.11) vs. ($1.10) last year
- Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics regains Nasdaq compliance
- Inhibikase target adjusted to $27 from $5 for split at H.C. Wainwright
